The scale of biopharmaceutical production is rapidly expanding around the bio cluster in Songdo International City, Incheon.
According to the Incheon Free Economic Zone Authority on the 18th, the total biopharmaceutical production capacity of the Songdo bio cluster is expected to increase from 1,035,000 liters last year to 2,140,000 liters in 2030.
Biopharmaceutical production capacity in Songdo has gradually grown from 50,000 liters in 2010 to 330,000 liters in 2015 and 560,000 liters in 2020.
The Incheon Free Economic Zone Authority noted that when Lotte Biologics' Plant 1 (120,000 liters) is completed at the end of this year, biopharmaceutical production capacity in Songdo will reach 1,155,000 liters.
Samsung Biologics has a production capacity of 785,000 liters. It plans to complete the second bio campus (Plants 5–8) by 2032 to expand capacity to 1,325,000 liters, and Lotte Biologics plans to sequentially build Plants 2 and 3 (each 120,000 liters).
Celltrion, which has a production capacity of 250,000 liters, is building a new drug product (DP) plant with the goal of completion this year and plans to begin production next year.
At the Bioprocess Human Resources Development Center on the Yonsei University Songdo International Campus, which opened at the end of last year, about 2,000 biopharmaceutical specialists are trained annually.